Low versus standard dose mCPP challenge in obsessive-compulsive patients

Area of Science:

• Neuroscience
• Psychopharmacology
• Clinical Psychology

Background:

• Meta-chlorophenylpiperazine (mCPP), a partial serotonergic agonist, has been associated with worsening obsessive-compulsive (OC) symptoms at a 0.5 mg/kg dose.
• Previous research on the 0.25 mg/kg mCPP dose was limited to healthy subjects, leaving its specific effects on OC patients uninvestigated.

Purpose of the Study:

• To evaluate the efficacy of a lower dose (0.25 mg/kg) of mCPP in specifically targeting and potentially exacerbating OC symptoms.
• To compare the effects of the low-dose mCPP against a standard dose (0.5 mg/kg) and placebo in OC patients.

Main Methods:

• A double-blind, controlled crossover study involving 12 patients diagnosed with OC disorder.
• Participants received oral administrations of 0.5 mg/kg mCPP, 0.25 mg/kg mCPP, or placebo on separate test days.
• Behavioral symptom severity was assessed using Visual Analogue Scale (VAS) ratings.

Main Results:

• The 0.25 mg/kg mCPP dose significantly worsened OC symptoms in 50% (6/12) of the patients.
• In contrast, the standard 0.5 mg/kg mCPP dose led to symptom worsening in only 8.3% (1/12) of patients.
• The standard dose showed a non-significant trend towards increased anxiety ratings, while the low dose had minimal anxiogenic effects.

Conclusions:

• The 0.25 mg/kg mCPP dose appears to elicit a specific worsening of OC symptoms with a reduced potential for inducing anxiety.
• These preliminary findings suggest a potential therapeutic or diagnostic application for lower mCPP doses in OC disorder.
• Further research with larger sample sizes and more sensitive rating scales is recommended to validate these results.